6,746 results on '"H1N1 influenza"'
Search Results
2. mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA.
- Author
-
Chaves, Lorena C. S., Orr-Burks, Nichole, Vanover, Daryll, Mosur, Varun V., Hosking, Sarah R., Kumar E. K., Pramod, Jeong, Hyeyoon, Jung, Younghun, Assumpção, José A. F., Peck, Hannah E., Nelson, Sarah L., Burke, Kaitlyn N., Garrison, McKinzie A., Arthur, Robert A., Claussen, Henry, Heaton, Nicholas S., Lafontaine, Eric R., Hogan, Robert J., Zurla, Chiara, and Santangelo, Philip J.
- Subjects
- *
INFLUENZA , *H1N1 influenza , *RNA , *VIRUS diseases , *RESPIRATORY infections , *MESSENGER RNA , *NEURAMINIDASE - Abstract
The CRISPR-Cas13 system has been proposed as an alternative treatment of viral infections. However, for this approach to be adopted as an antiviral, it must be optimized until levels of efficacy rival or exceed the performance of conventional approaches. To take steps toward this goal, we evaluated the influenza viral RNA degradation patterns resulting from the binding and enzymatic activity of mRNA-encoded LbuCas13a and two crRNAs from a prior study, targeting PB2 genomic and messenger RNA. We found that the genome targeting guide has the potential for significantly higher potency than originally detected, because degradation of the genomic RNA is not uniform across the PB2 segment, but it is augmented in proximity to the Cas13 binding site. The PB2 genome targeting guide exhibited high levels (>1 log) of RNA degradation when delivered 24 hours post-infection in vitro and maintained that level of degradation over time, with increasing multiplicity of infection (MOI), and across modern influenza H1N1 and H3N2 strains. Chemical modifications to guides with potent LbuCas13a function, resulted in nebulizer delivered efficacy (>1–2 log reduction in viral titer) in a hamster model of influenza (Influenza A/H1N1/California/04/09) infection given prophylactically or as a treatment (post-infection). Maximum efficacy was achieved with two doses, when administered both pre- and post-infection. This work provides evidence that mRNA-encoded Cas13a can effectively mitigate Influenza A infections opening the door to the development of a programmable approach to treating multiple respiratory infections. Author summary: For the CRISPR-Cas13 system to be adopted as an alternative treatment of viral infections, it must reach levels of efficacy that rival or exceed the performance of conventional approaches. We evaluated the degradation patterns resulting from the binding and enzymatic activity of mRNA-encoded LbuCas13a and two previously identified crRNAs, targeting conserved PB2 genomic and messenger RNA sequences. The genome targeting guide displayed higher potency than originally detected, because RNA degradation was augmented near the guide binding site, leading to 1-log of RNA degradation in vitro, which persisted over time, with increasing multiplicity of infection (MOI), and across modern influenza H1N1 and H3N2 strains. The addition of chemical modifications to the guide resulted in 1-2-log reduction in viral titer upon nebulizer delivery prophylactically or as a treatment in a hamster model of influenza. Maximum efficacy was achieved with two doses administered pre- and post-infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Profiling lipid mediators in serum from children with H1N1 influenza.
- Author
-
Chen, Weijun, Gu, Yitao, Ma, Yongjun, Dong, Lele, Pan, Liangxuan, Ji, Chai, Guo, Lanlan, Qi, Lianxin, Zhang, Yuanyuan, and Gao, Fei
- Subjects
- *
H1N1 influenza , *INFLUENZA A virus, H1N1 subtype , *LIQUID chromatography-mass spectrometry , *ADULT respiratory distress syndrome , *BLOOD lipids - Abstract
Influenza A virus subtype H1N1 can cause severe acute respiratory distress syndrome and death in young children and elderly individuals. H1N1 initiates inflammatory responses that aim to contain and eliminate microbial invaders. Various lipid mediators (LMs) are biosynthesized and play a critical role in fighting viruses during inflammation; thus, by profiling the LMs in patients, researchers can obtain mechanistic insights into diseases, such as the pathways disrupted. To date, the relationship between molecular alterations in LMs and the pathogenesis of H1N1 influenza in children is poorly understood. Here, we employed a targeted liquid chromatography coupled with tandem mass spectrometry (LC‒MS/MS) to profile LMs in serum from children with H1N1 influenza (H1N1 children) and recovered children. We found that 22 LM species were altered in H1N1 children with mild symptoms. Analysis of the LM profiles of recovered children revealed a decrease in the levels of thromboxane B2 (TxB2) and thromboxane B3 (TxB3) and an increase in the levels of other 8 altered LM species associated with H1N1 influenza, including cytochrome P450 (CYP) enzyme-derived dihydroxyeicosatrienoic acids (DiHETrEs) and hydroxyeicosatetraenoic acids (HETEs) from arachidonic acid (AA), and epoxyoctadecamonoenoic acids (EpOMEs) from linoleic acid (LA). Taken together, the results of this study revealed that serum LMs change dynamically in H1N1 children with mild symptoms. The dramatically altered LMs in H1N1 children could serve as a basis for potential therapeutics or adjuvants against H1N1 influenza. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. A Live Attenuated H1N1 Influenza Vaccine Based on the Mutated M Gene.
- Author
-
Yi, Yinglei, Zhang, Hongbo, An, Youcai, and Chen, Ze
- Subjects
INFLUENZA vaccines ,DNA vaccines ,H1N1 influenza ,INFLUENZA viruses ,IMMUNE response - Abstract
The influenza vaccines currently approved for clinical use mainly include inactivated influenza virus vaccines and live attenuated influenza vaccines (LAIVs). LAIVs have multiple advantages, such as ease of use and strong immunogenicity, and can provide cross-protection. In this study, the M gene of the PR8 virus was mutated as follows (G11T, C79G, G82C, C85G, and C1016A), and a live attenuated influenza virus containing the mutated M gene was rescued and obtained using reverse genetic technology as a vaccine candidate. The replication ability of the rescued virus was significantly weakened in both MDCK cells and mice with attenuated virulence. Studies on immunogenicity found that 1000 TCID
50 of mutated PR8 (mPR8) can prime strong humoral and cellular immune responses. Single-dose immunization of 1000 TCID50 mPR8 was not only able to counter the challenge of the homologous PR8 virus but also provided cross-protection against the heterologous H9N2 virus. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.
- Author
-
Chun-li Lu, Liu-qing Yang, Xin-yan Jin, Thomas Friedemann, Yu-fei Li, Xue-han Liu, Xiao-ying Chen, Xiang-yun Zou, Bing-rui Zhang, Fu-xiang Wang, Yuan-long Lin, Yi-min Tang, Meng-li Cao, Ya-lin Jiang, You-fang Gao, Kui Liu, Zhen-gang Tao, Nicola Robinson, Sven Schröder, and Jian-ping Liu
- Subjects
HERBAL medicine ,CHINESE medicine ,H1N1 influenza ,COVID-19 ,COMMON cold ,SUMATRIPTAN - Abstract
Background: The COVID-19 pandemic has had a profound global impact, although the majority of recently infected cases have presented with mild to moderate symptoms. Previous clinical studies have demonstrated that Shufeng Jiedu (SFJD) capsule, a Chinese herbal patent medicine, effectively alleviates symptoms associated with the common cold, H1N1 influenza, and COVID-19. This study aimed to assess the efficacy and safety of SFJD capsules in managing symptoms of mild to moderate COVID-19 infection. Methods: A randomized, double-blind, placebo-controlled trial was conducted from May to December 2022 at two hospitals in China. Mild and moderate COVID-19-infected patients presenting respiratory symptoms within 3 days from onset were randomly assigned to either the SFJD or placebo groups in a 1:1 ratio. Individuals received SFJD capsules or a placebo three times daily for five consecutive days. Participants were followed up for more than 14 days after their RT-PCR nucleoid acid test for SARS-CoV-2 turned negative. The primary outcome measure was time to alleviate COVID-19 symptoms from baseline until the end of follow-up. Results: A total of 478 participants were screened; ultimately, 407 completed the trial after randomization (SFJD, n = 203; placebo, n = 204). No statistically significant difference in baseline parameters was observed between the two groups. The median time to alleviate all symptoms was 7 days in the SFJD group compared to 8 days in the placebo group (p = 0.037). Notably, the SFJD group significantly attenuated fever/chills (p = 0.04) and headache (p = 0.016) compared to the placebo group. Furthermore, the median time taken to reach normal body temperature within 24 h was reduced by 7 hours in the SFJD group compared to the placebo group (p = 0.033). No deaths or instances of serious or critical conditions occurred during this trial period; moreover, no serious adverse events were reported. Conclusion: The trial was conducted in a unique controlled hospital setting, and the 5-day treatment with SFJD capsules resulted in a 1-day reduction in overall symptoms, particularly headache and fever/chills, among COVID-19-infected participants with mild or moderate symptoms. Compared to placebo, SFJD capsules were found to be safe with fewer side effects. SFJD capsules could potentially serve as an effective treatment for alleviating mild to moderate symptoms of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.
- Author
-
Garg, Naveen, Tellier, Guy, Vale, Noah, Kluge, Jon, Portman, Jonathan L., Markowska, Anna, and Tussey, Lynda
- Subjects
- *
H1N1 influenza , *INFLUENZA vaccines , *IMMUNE response , *SEASONAL influenza , *ANTIBODY titer , *TRANSCRANIAL direct current stimulation , *SUMATRIPTAN - Abstract
Background: The MIMIX platform is a novel microneedle array patch (MAP) characterized by slowly dissolving microneedle tips that deploy into the dermis following patch application. We describe safety, reactogenicity, tolerability and immunogenicity for MIMIX MAP vaccination against influenza. Methodology: The trial was a Phase 1, exploratory, first-in-human, parallel randomized, rater, participant, study analyst-blinded, placebo-controlled study in Canada. Forty-five healthy participants (18 to 39 years of age, inclusive) were randomized in a 1:1:1 ratio to receive either 15 μg or 7.5 μg of an H1N1 influenza vaccine, or placebo delivered via MIMIX MAP to the volar forearm. A statistician used a computer program to create a randomization scheme with a block size of 3. Post-treatment follow-up was approximately 180 days. Primary safety outcomes included the incidence of study product related serious adverse events and unsolicited events within 180 days, solicited application site and systemic reactogenicity through 7 days after administration and solicited application site erythema and/or pigmentation 14, 28, 56 and 180 days after administration. Immunogenicity outcomes included antibody titers and percentage of seroconversion (SCR) and seroprotection (SPR) rates determined by the hemagglutination inhibition (HAI) assay. Exploratory outcomes included virus microneutralization (MN) titers, durability and breadth of the immune response. The trial was registered with ClinicalTrials.gov, number NCT 06125717. Findings: Between July 7, 2022 and March 13, 2023 45 participants were randomized to a treatment group. One participant was lost to follow up in the 15 μg group and 1 participant withdrew from the 7.5 μg dose group. Safety analyses included n = 15 per group, immunogenicity analyses included n = 14 for the 15 μg and 7.5 μg treatment groups and n = 15 for the placebo group. No SAEs were reported in any of the treatment groups. All treatment groups reported solicited local events within 7 days after vaccination, with mild (Grade 1) erythema being the most frequent symptom reported. Other local symptoms reported included mostly mild (Grade 1) induration/swelling, itching, pigmentation, skin flaking, and tenderness. Within 7 days after vaccination, 2 participants (4.4%) reported moderate (Grade 2) erythema, 1 participant (2.2%) reported moderate (Grade 2) induration/swelling, and 1 participant (2.2%) reported moderate (Grade 2) itching. There was an overall reduction in erythema and pigmentation reported on Days 15, 29, 57, and 180 among all treatment groups. Systemic symptoms reported within 7 days after vaccination, included mild (Grade 1) fatigue reported among all treatment groups, and mild (Grade 1) headache reported by 1 participant in the 7.5 μg treatment group. No study drug related severe symptoms were reported in the study. Group mean fold rises in HAI titers ranged between 8.7 and 12-fold, SCRs were >76% and SPRs were >92% for both VX-103 dose groups thereby fulfilling serological criteria established by the EMA and FDA for seasonal influenza vaccines. Longitudinal assessments demonstrate persistence of the immune response through at least Day 180. Conclusions: The MIMIX MAP platform is safe, well tolerated and elicits robust antibody responses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Exploring the Underlying Mechanisms of Qingxing Granules Treating H1N1 Influenza Based on Network Pharmacology and Experimental Validation.
- Author
-
Du, Hujun, Zhang, Lianying, Sun, Haoxiang, Zheng, Shaoqin, Zhang, Hongying, Yuan, Shijia, Zhou, Jiuyao, Fang, Zihao, Song, Jianping, Mei, Manxue, and Deng, Changsheng
- Subjects
- *
H1N1 influenza , *HIGH performance liquid chromatography , *CHINESE medicine , *PHARMACOLOGY , *MOLECULAR docking , *SEASONAL influenza , *SWINE influenza - Abstract
Background: H1N1 is one of the major subtypes of influenza A virus (IAV) that causes seasonal influenza, posing a serious threat to human health. A traditional Chinese medicine combination called Qingxing granules (QX) is utilized clinically to treat epidemic influenza. However, its chemical components are complex, and the potential pharmacological mechanisms are still unknown. Methods: QX's effective components were gathered from the TCMSP database based on two criteria: drug-likeness (DL ≥ 0.18) and oral bioavailability (OB ≥ 30%). SwissADME was used to predict potential targets of effective components, and Cytoscape was used to create a "Herb-Component-Target" network for QX. In addition, targets associated with H1N1 were gathered from the databases GeneCards, OMIM, and GEO. Targets associated with autophagy were retrieved from the KEGG, HAMdb, and HADb databases. Intersection targets for QX, H1N1 influenza, and autophagy were identified using Venn diagrams. Afterward, key targets were screened using Cytoscape's protein–protein interaction networks built using the database STRING. Biological functions and signaling pathways of overlapping targets were observed through GO analysis and KEGG enrichment analysis. The main chemical components of QX were determined by high-performance liquid chromatography (HPLC), followed by molecular docking. Finally, the mechanism of QX in treating H1N1 was validated through animal experiments. Results: A total of 786 potential targets and 91 effective components of QX were identified. There were 5420 targets related to H1N1 and 821 autophagy-related targets. The intersection of all targets of QX, H1N1, and autophagy yielded 75 intersecting targets. Ultimately, 10 core targets were selected: BCL2, CASP3, NFKB1, MTOR, JUN, TNF, HSP90AA1, EGFR, HIF1A, and MAPK3. Identification of the main chemical components of QX by HPLC resulted in the separation of seven marker ingredients within 195 min, which are amygdalin, puerarin, baicalin, phillyrin, wogonoside, baicalein, and wogonin. Molecular docking results showed that BCL2, CASP3, NFKB1, and MTOR could bind well with the compounds. In animal studies, QX reduced the degenerative alterations in the lung tissue of H1N1-infected mice by upregulating the expression of p-mTOR/mTOR and p62 and downregulating the expression of LC3, which inhibited autophagy. Conclusions: According to this study's network pharmacology analysis and experimental confirmation, QX may be able to treat H1N1 infection by regulating autophagy, lowering the expression of LC3, and increasing the expression of p62 and p-mTOR/mTOR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Dynamic Patterns and Predominance of Respiratory Pathogens Post-COVID-19: Insights from a Two-Year Analysis.
- Author
-
AlBahrani, Salma, AlZahrani, Samira Jamaan, Al-Maqati, Thekra N., Almehbash, Atheer, Alshammari, Anfal, Bujlai, Refan, Ba Taweel, Sarah, Almasabi, Fares, AlAmari, Abdullah, and Al-Tawfiq, Jaffar A.
- Subjects
EMERGENCY room visits ,H1N1 influenza ,COVID-19 pandemic ,RESPIRATORY infections ,DIAGNOSTIC use of polymerase chain reaction ,COVID-19 - Abstract
Introduction: Respiratory tract infections (RTIs) stand out as the most frequent causes leading to visits to the emergency department and hospitalizations. This study aims to assess the types and prevalence of respiratory infections across two years following the end of the COVID-19 pandemic. Methods: Patients presenting with an influenza-like illness (ILI) were tested using multiplex RT-PCR (QIAstat-Dx, Qiagen). The multiplexed RT- PCR test detects 21 respiratory viruses and bacteria. Results: During the study period, PCR test was done on a total of 1,790 samples were tested, and 712 (40%) were positive for a total of 796 pathogens. The mean age (± SD) of the participants was 20.1 ± 28.4 years in 2022 and 21.9 ± 27.6 years in 2023. Among the detected pathogens, the most prevalent were Rhinovirus/Enterovirus 222 (12.4%), followed by RSV A&B (103 cases, 5.7%), and H1N1 Influenza (77 cases, 4.3%). Additionally, Influenza A/B constituted 172 (9.6%) while parainfluenza constituted (58, 3.2%). SARS-CoV-2 was identified in 3.97% of the samples. Over the two-year period, the monthly pattern of the identified pathogens exhibited fluctuations in the prevalence. Furthermore, variations were observed in the detected pathogens across different age groups. Conclusion: In addition to adding significant knowledge to the field of respiratory viral infections, this study emphasizes the necessity of ongoing research and surveillance for the detection and characterization of respiratory viruses, particularly those with the potential for emergence. Such studies would also require setting up a strategy for genotyping and/or sequencing of viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Extracorporeal membrane oxygenation technology for adults: an evidence mapping based on systematic reviews.
- Author
-
Xie, Kai, Jing, Hui, Guan, Shengnan, Kong, Xinxin, Ji, Wenshuai, Du, Chen, Jia, Mingyan, and Wang, Haifeng
- Subjects
EXTRACORPOREAL membrane oxygenation ,H1N1 influenza ,CARDIAC arrest ,ADULTS - Abstract
Background: Extracorporeal membrane oxygenation (ECMO) is a cutting-edge life-support measure for patients with severe cardiac and pulmonary illnesses. Although there are several systematic reviews (SRs) about ECMO, it remains to be seen how quality they are and how efficacy and safe the information about ECMO they describe is in these SRs. Therefore, performing an overview of available SRs concerning ECMO is crucial. Methods: We searched four electronic databases from inception to January 2023 to identify SRs with or without meta-analyses. The Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) tool, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system were used to assess the methodological quality, and evidence quality for SRs, respectively. A bubble plot was used to visually display clinical topics, literature size, number of SRs, evidence quality, and an overall estimate of efficacy. Results: A total of 17 SRs met eligibility criteria, which were combined into 9 different clinical topics. The methodological quality of the included SRs in this mapping was "Critically low" to "Moderate". One of the SRs was high-quality evidence, three on moderate, three on low, and two on very low-quality evidence. The most prevalent study used to evaluate ECMO technology was observational or cohort study with frequently small sample sizes. ECMO has been proven beneficial for severe ARDS and ALI due to the H1N1 influenza infection. For ARDS, ALF or ACLF, and cardiac arrest were concluded to be probably beneficial. For dependent ARDS, ARF, ARF due to the H1N1 influenza pandemic, and cardiac arrest of cardiac origin came to an inconclusive conclusion. There was no evidence for a harmful association between ECMO and the range of clinical topics. Conclusions: There is limited available evidence for ECMO that large sample, multi-center, and multinational RCTs are needed. Most clinical topics are reported as beneficial or probably beneficial of SRs for ECMO. Evidence mapping is a valuable and reliable methodology to identify and present the existing evidence about therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Long-term outcomes of survivors with influenza A H1N1 virus-induced severe pneumonia and ARDS: a single-center prospective cohort study.
- Author
-
Xiao Tang, Xiao-Li Xu, Na Wan, Yu Zhao, Rui Wang, Xu-Yan Li, Ying Li, Li Wang, Hai-Chao Li, Yue Gu, Chun-Yan Zhang, Qi Yang, Zhao-Hui Tong, and Bing Sun
- Subjects
H1N1 influenza ,PULMONARY fibrosis ,ADULT respiratory distress syndrome ,PNEUMONIA ,QUALITY of life ,SWINE influenza - Abstract
Introduction: Systematic evaluation of long-term outcomes in survivors of H1N1 is still lacking. This study aimed to characterize long-term outcomes of severe H1N1-induced pneumonia and acute respiratory distress syndrome (ARDS). Method: This was a single-center, prospective, cohort study. Survivors were followed up for four times after discharge from intensive care unit (ICU) by lung high-resolution computed tomography (HRCT), pulmonary function assessment, 6-minute walk test (6MWT), and SF-36 instrument. Result: A total of 60 survivors of H1N1-induced pneumonia and ARDS were followed up for four times. The carbon monoxide at single breath (D
LCO ) of predicted values and the 6MWT results didn't continue improving after 3 months. Health-related quality of life didn't change during the 12 months after ICU discharge. Reticulation or interlobular septal thickening on HRCT did not begin to improve significantly until the 12-month follow-up. The DLCO of predicted values showed negative correlation with the severity degree of primary disease and reticulation or interlobular septal thickening, and a positive correlation with physical functioning. The DLCO of predicted values and reticulation or interlobular septal thickening both correlated with the highest tidal volume during mechanical ventilation. Levels of fibrogenic cytokines had a positive correlation with reticulation or interlobular septal thickening. Conclusion: The improvements in pulmonary function and exercise capacity, imaging, and health-related quality of life had different time phase and impact on each other during 12 months of follow-up. Long-term outcomes of pulmonary fibrosis might be related to the lung injury and excessive lung fibroproliferation at the early stage during ICU admission. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
11. Pyrogallol protects against influenza A virus‐triggered lethal lung injury by activating the Nrf2–PPAR‐γ–HO‐1 signaling axis.
- Author
-
Zhou, Beixian, Wang, Linxin, Yang, Sushan, Liang, Yueyun, Zhang, Yuehan, Liu, Xuanyu, Pan, Xiping, and Li, Jing
- Subjects
LUNG injuries ,PEROXISOME proliferator-activated receptors ,INFLUENZA ,H1N1 influenza ,VIRUS diseases ,NF-kappa B ,NUCLEAR receptors (Biochemistry) - Abstract
Pyrogallol, a natural polyphenol compound (1,2,3‐trihydroxybenzene), has shown efficacy in the therapeutic treatment of disorders associated with inflammation. Nevertheless, the mechanisms underlying the protective properties of pyrogallol against influenza A virus infection are not yet established. We established in this study that pyrogallol effectively alleviated H1N1 influenza A virus‐induced lung injury and reduced mortality. Treatment with pyrogallol was found to promote the expression and nuclear translocation of nuclear factor erythroid‐2‐related factor 2 (Nrf2) and peroxisome proliferator‐activated receptor gamma (PPAR‐γ). Notably, the activation of Nrf2 by pyrogallol was involved in elevating the expression of PPAR‐γ, both of which act synergistically to enhance heme oxygenase‐1 (HO‐1) synthesis. Blocking HO‐1 by zinc protoporphyrin (ZnPP) reduced the suppressive impact of pyrogallol on H1N1 virus‐mediated aberrant retinoic acid‐inducible gene‐I‐nuclear factor kappa B (RIG‐I–NF‐κB) signaling, which thus abolished the dampening effects of pyrogallol on excessive proinflammatory mediators and cell death (including apoptosis, necrosis, and ferroptosis). Furthermore, the HO‐1‐independent inactivation of janus kinase 1/signal transducers and activators of transcription (JAK1/STATs) and the HO‐1‐dependent RIG‐I‐augmented STAT1/2 activation were both abrogated by pyrogallol, resulting in suppression of the enhanced transcriptional activity of interferon‐stimulated gene factor 3 (ISGF3) complexes, thus prominently inhibiting the amplification of the H1N1 virus‐induced proinflammatory reaction and apoptosis in interferon‐beta (IFN‐β)‐sensitized cells. The study provides evidence that pyrogallol alleviates excessive proinflammatory responses and abnormal cell death via HO‐1 induction, suggesting it could be a potential agent for treating influenza. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Enhancing the use of T cells as a universal preventive measure against H3N2 influenza: Mechanism and implications.
- Author
-
Bhatt, Jugal Hiren, Kagathara, Nency, Mehta, Kahan, Joshi, Maurya, and Omar, Mohamed A.
- Subjects
T cells ,H7N9 Influenza ,INFLUENZA ,BACTERIAL vaccines ,T cell receptors ,INFLUENZA A virus, H1N1 subtype ,PANDEMIC preparedness ,H1N1 influenza - Abstract
The article addresses the need to enhance T cell-based strategies to counteract the H3N2 influenza virus, highlighting their potential as universal preventive measures. Topics discussed include the challenges of accurate diagnosis and effective vaccination, the critical role of T cells in combating influenza, and the need for further research and standardized methods to optimize T cell vaccine efficacy.
- Published
- 2024
- Full Text
- View/download PDF
13. Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome (ARDS)
- Published
- 2023
14. mRNA vaccines encoding computationally optimized hemagglutinin elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses isolated between 2018-2020.
- Author
-
Allen, James D. and Ross, Ted M.
- Subjects
INFLUENZA A virus, H1N1 subtype ,SEASONAL influenza ,H1N1 influenza ,MESSENGER RNA ,HEMAGGLUTININ - Abstract
Background: The implementation of mRNA vaccines against COVID-19 has successfully validated the safety and efficacy of the platform, while at the same time revealing the potential for their applications against other infectious diseases. Traditional seasonal influenza vaccines often induce strain specific antibody responses that offer limited protection against antigenically drifted viruses, leading to reduced vaccine efficacy. Modern advances in viral surveillance and sequencing have led to the development of in-silico methodologies for generating computationally optimized broadly reactive antigens (COBRAs) to improve seasonal influenza vaccines. Methods: In this study, immunologically naïve mice were intramuscularly vaccinated with mRNA encoding H1 and H3 COBRA hemagglutinins (HA) or wild-type (WT) influenza HAs encapsulated in lipid nanoparticles (LNPs). Results: Mice vaccinated with H1 and H3 COBRA HA-encoding mRNA vaccines generated robust neutralizing serum antibody responses against more antigenically distinct contemporary and future drifted H1N1 and H3N2 influenza strains than those vaccinated with WT H1 and H3 HA-encoding mRNA vaccines. The H1 and H3 COBRA HA-encoding mRNA vaccines also prevented influenza illness, including severe disease in the mouse model against H1N1 and H3N2 viruses. Conclusions: This study highlights the potential benefits of combining universal influenza antigen design technology with modern vaccine delivery platforms and exhibits how these vaccines can be advantageous over traditional WT vaccine antigens at eliciting superior protective antibody responses against a broader number of influenza virus isolates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Influenza a H1N1 infection complicated with encephalopathy and acute pancreatitis: a case report.
- Author
-
Cui, Junhao, Jia, Wanyu, Li, Peng, Zhang, Xue, Li, Zheng, and Song, Chunlan
- Subjects
H1N1 influenza ,PANCREATITIS ,BRAIN diseases ,INFECTION ,INFLUENZA - Abstract
This paper reports a case of influenza complicated with influenza associated encephalopathy complicated with acute pancreatitis. This kind of disease is relatively rare, we hope to draw people's attention to it in order to improve early detection and prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Anti‐influenza A (H1N1) virus effect of gallic acid through inhibition of virulent protein production and association with autophagy.
- Author
-
Chang, Cheng‐Chieh, You, Huey‐Ling, Su, Huey‐Jen, Hung, I‐Ling, Kao, Chao‐Wei, and Huang, Sheng‐Teng
- Subjects
- *
GALLIC acid , *INFLUENZA A virus, H1N1 subtype , *H1N1 influenza , *AUTOPHAGY , *WESTERN immunoblotting - Abstract
Influenza remains one of the most serious infectious diseases. Gallic acid is one of the most common and representative phenolic acids found in various plants. This is an interesting subject to explore how gallic acid could inhibit H1N1 influenza virus infection by reducing the production of virulent proteins and interrupting autophagy machinery for influenza virus replication on the host cell. Cellular viability was assessed by XTT assay. The inhibitory effects on the H1N1 influenza virus were assessed by hemagglutination assay, plaque assay, and qRT‐PCR. Western blot analysis was used for detecting protein levels of M1, M2, NP, LC3B, and beclin‐1. Autophagy activity was demonstrated by acridine orange staining assay. The result demonstrated that there was no cytotoxic effect of gallic acid on A549 cells, and gallic acid could restore the cellular viability of H1N1 influenza virus‐infected A549 cells within the experimental concentration treatment. Moreover, gallic acid could effectively restrain viral activity of the H1N1 influenza virus. After the treatment of gallic acid, the production of virulent H1N1 influenza virus proteins, that is, M1, M2, and NP protein were reduced. As for autophagic mechanism, both of the LC3B II conversion and the level ratio of LC3B II to LC3B I were notably decreased. The acridine orange staining assay also revealed decreased accumulation of autophagosomes in H1N1 influenza virus‐infected cells. In conclusion, gallic acid suppresses H1N1 influenza viral infectivity through restoration of autophagy pathway and inhibition of virulent M1, M2, and NP protein production. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Nucleoprotein reassortment enhanced transmissibility of H3 1990.4.a clade influenza A virus in swine.
- Author
-
Thomas, Megan N., Zanella, Giovana Ciacci, Cowan, Brianna, Caceres, C. Joaquin, Rajao, Daniela S., Perez, Daniel R., Gauger, Phillip C., Baker, Amy L. Vincent, and Anderson, Tavis K.
- Subjects
- *
INFLUENZA A virus , *INFLUENZA viruses , *REVERSE genetics , *H1N1 influenza , *H7N9 Influenza , *VIRAL shedding , *SWINE influenza - Abstract
The increased detection of H3 C-IVA (1990.4.a) clade influenza A viruses (IAVs) in US swine in 2019 was associated with a reassortment event to acquire an H1N1pdm09 lineage nucleoprotein (pdmNP) gene, replacing a TRIG lineage NP (trigNP). We hypothesized that acquiring the pdmNP conferred a selective advantage over prior circulating H3 viruses with a trigNP. To investigate the role of NP reassortment in transmission, we identified two contemporary 1990.4.a representative strains (NC/19 and MN/18) with different evolutionary origins of the NP gene. A reverse genetics system was used to generate wild-type (wt) strains and swap the pdm and TRIG lineage NP genes, generating four viruses: wtNC/19-pdmNP, NC/19-trigNP, wtMN/18-trigNP, and MN/18-pdmNP. The pathogenicity and transmission of the four viruses were compared in pigs. All four viruses infected 10 primary pigs and transmitted to five indirect contact pigs per group. Pigs infected via contact with MN/18-pdmNP shed virus 2 days earlier than pigs infected with wtMN/18-trigNP. The inverse did not occur for wtNC/19-pdmNP and NC/19-trigNP. This suggests that pdmNP reassortment resulted in a combination of genes that improved transmission efficiency when paired with the 1990.4.a hemagglutinin (HA). This is likely a multigenic trait, as replacing the trigNP gene did not diminish the transmission of a wild-type IAV in swine. This study demonstrates how reassortment and evolutionary change of internal genes can result in more transmissible viruses that influence HA clade detection frequency. Thus, rapidly identifying novel reassortants paired with dominant hemagglutinin/neuraminidase may improve the prediction of strains to include in vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Prior Influenza Infection Mitigates SARS-CoV-2 Disease in Syrian Hamsters.
- Author
-
Di Pietro, Caterina, Haberman, Ann M., Lindenbach, Brett D., Smith, Peter C., Bruscia, Emanuela M., Allore, Heather G., Vander Wyk, Brent, Tyagi, Antariksh, and Zeiss, Caroline J.
- Subjects
- *
GOLDEN hamster , *SARS-CoV-2 , *INFLUENZA , *H1N1 influenza , *LUNG diseases - Abstract
Seasonal infection rates of individual viruses are influenced by synergistic or inhibitory interactions between coincident viruses. Endemic patterns of SARS-CoV-2 and influenza infection overlap seasonally in the Northern hemisphere and may be similarly influenced. We explored the immunopathologic basis of SARS-CoV-2 and influenza A (H1N1pdm09) interactions in Syrian hamsters. H1N1 given 48 h prior to SARS-CoV-2 profoundly mitigated weight loss and lung pathology compared to SARS-CoV-2 infection alone. This was accompanied by the normalization of granulocyte dynamics and accelerated antigen-presenting populations in bronchoalveolar lavage and blood. Using nasal transcriptomics, we identified a rapid upregulation of innate and antiviral pathways induced by H1N1 by the time of SARS-CoV-2 inoculation in 48 h dual-infected animals. The animals that were infected with both viruses also showed a notable and temporary downregulation of mitochondrial and viral replication pathways. Quantitative RT-PCR confirmed a decrease in the SARS-CoV-2 viral load and lower cytokine levels in the lungs of animals infected with both viruses throughout the course of the disease. Our data confirm that H1N1 infection induces rapid and transient gene expression that is associated with the mitigation of SARS-CoV-2 pulmonary disease. These protective responses are likely to begin in the upper respiratory tract shortly after infection. On a population level, interaction between these two viruses may influence their relative seasonal infection rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. HIF-1α promotes virus replication and cytokine storm in H1N1 virus-induced severe pneumonia through cellular metabolic reprogramming.
- Author
-
Xiaoxiao Meng, Yong Zhu, Wenyu Yang, Jiaxiang Zhang, Wei Jin, Rui Tian, Zhengfeng Yang, and Ruilan Wang
- Subjects
PNEUMONIA ,H1N1 influenza ,CYTOKINES ,HYPOXIA-inducible factor 1 ,GLYCOLYSIS - Abstract
The mortality of patients with severe pneumonia caused by infection is closely related to viral replication H1N1 and cytokine storm. However, the specific mechanisms triggering virus replication and cytokine storm are still not fully elucidated. Here, we identified hypoxia inducible factor-1α (HIF-1α) as one of the major host molecules that facilitates H1N1 virus replication followed by cytokine storm in alveolar epithelial cells. Specifically, HIF-1α protein expression is upregulated after H1N1 infection. Deficiency of HIF-1α attenuates pulmonary injury, viral replication and cytokine storm in vivo. In addition, viral replication and cytokine storm were inhibited after HIF-1α knockdown in vitro. Mechanistically, the invasion of H1N1 virus into alveolar epithelial cells leads to a shift in glucose metabolism to glycolysis, with rapid production of ATP and lactate. Inhibition of glycolysis significantly suppresses viral replication and inflammatory responses. Further analysis revealed that H1N1-induced HIF-1α can promote the expression of hexokinase 2 (HK2), the key enzyme of glycolysis, and then not only provide energy for the rapid replication of H1N1 virus but also produce lactate, which reduces the accumulation of the MAVS/RIG-I complex and inhibits IFN-α/β production. In conclusion, this study demonstrated that the upregulation of HIF-1α by H1N1 infection augments viral replication and cytokine storm by cellular metabolic reprogramming toward glycolysis mainly through upregulation of HK2, providing a theoretical basis for finding potential targets for the treatment of severe pneumonia caused by H1N1 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Naturally occurring PAE206K point mutation in 2009 H1N1 pandemic influenza viruses impairs viral replication at high temperatures.
- Author
-
Mengmeng Cao, Qiannan Jia, Jinghua Li, Lili Zhao, Li zhu, Yufan Zhang, Shan Li, and Tao Deng
- Subjects
H1N1 influenza ,INFLUENZA A virus ,POLYMERASES ,VIRAL replication - Abstract
The emergence of influenza virus A pandemic H1N1 in April 2009 marked the first pandemic of the 21st century. In this study, we observed significant differences in the polymerase activities of two clinical 2009 H1N1 influenza A virus isolates from Chinese and Japanese patients. Sequence comparison of the three main protein subunits (PB2, PB1, and PA) of the viral RNA-dependent RNA polymerase complex and subsequent mutational analysis revealed that a single amino acid substitution (E206K) was responsible for the observed impaired replication phenotype. Further in vitro experiments showed that presence of PA
E206K decreased the replication of influenza A/ WSN/33 virus in mammalian cells and a reduction in the virus's pathogenicity in vivo. Mechanistic studies revealed that PAE206K is a temperature-sensitive mutant associated with the inability to transport PB1-PA complex to the nucleus at high temperature (39.5 °C). Hence, this naturally occurring variant in the PA protein represents an ideal candidate mutation for the development of live attenuated influenza vaccines. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
21. Uncovering the burden of Influenza in children in Portugal, 2008–2018.
- Author
-
Caldas Afonso, Alberto, Gouveia, Catarina, Januário, Gustavo, Carmo, Mafalda, Lopes, Hugo, Bricout, Hélène, Gomes, Catarina, and Froes, Filipe
- Subjects
- *
INFLUENZA , *H1N1 influenza , *PUBLIC hospitals , *INFLUENZA viruses , *HOSPITAL mortality - Abstract
Background: Despite their higher risk of developing severe disease, little is known about the burden of influenza in Portugal in children aged < 5 years old. This study aims to cover this gap by estimating the clinical and economic burden of severe influenza in children, in Portugal, during ten consecutive influenza seasons (2008/09-2017/18). Methods: We reviewed hospitalizations in children aged < 5 years old using anonymized administrative data covering all public hospitals discharges in mainland Portugal. The burden of hospitalization and in-hospital mortality directly coded as due to influenza was supplemented by the indirect burden calculated from excess hospitalization and mortality (influenza-associated), estimated for four groups of diagnoses (pneumonia or influenza, respiratory, respiratory or cardiovascular, and all-cause), through cyclic regression models integrating the incidence of influenza. Means were reported excluding the H1N1pdm09 pandemic (2009/10). Results: The mean annual number of hospitalizations coded as due to influenza was 189 (41.3 cases per 100,000 children aged < 5 years old). Hospitalization rates decreased with increasing age. Nine-in-ten children were previously healthy, but the presence of comorbidities increased with age. Children stayed, on average, 6.1 days at the hospital. Invasive mechanical ventilation was used in 2.4% of hospitalizations and non-invasive in 3.1%. Influenza-associated excess hospitalizations between 2008 and 2018 were estimated at 1,850 in pneumonia or influenza, 1,760 in respiratory, 1,787 in respiratory or cardiovascular, and 1,879 in all-cause models. A total of 95 influenza-associated excess deaths were estimated in all-cause, 14 in respiratory or cardiovascular, and 9 in respiratory models. Over ten years, influenza hospitalizations were estimated to have cost the National Health Service at least €2.9 million, of which 66.5% from healthy children. Conclusions: Influenza viruses led to a high number of hospitalizations in children. Most were previously healthy. Results should lead to a reflection on the adequate preventive measures to protect this age group. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. The Identification Distinct Antiviral Factors Regulated Influenza Pandemic H1N1 Infection.
- Author
-
Wang, Baoxin, Zheng, Hao, Dong, Xia, Zhang, Wenhua, Wu, Junjing, Chen, Hongbo, Zhang, Jing, and Zhou, Ao
- Subjects
- *
H1N1 influenza , *CELL receptors , *IMMUNOREGULATION , *SWINE influenza , *CYTOKINE release syndrome , *CELLULAR signal transduction , *VIRUS diseases - Abstract
Influenza pandemic with H1N1 (H1N1pdms) causes severe lung damage and "cytokine storm," leading to higher mortality and global health emergencies in humans and animals. Explaining host antiviral molecular mechanisms in response to H1N1pdms is important for the development of novel therapies. In this study, we organised and analysed multimicroarray data for mouse lungs infected with different H1N1pdm and nonpandemic H1N1 strains. We found that H1N1pdms infection resulted in a large proportion of differentially expressed genes (DEGs) in the infected lungs compared with normal lungs, and the number of DEGs increased markedly with the time of infection. In addition, we found that different H1N1pdm strains induced similarly innate immune responses and the identified DEGs during H1N1pdms infection were functionally concentrated in defence response to virus, cytokine-mediated signalling pathway, regulation of innate immune response, and response to interferon. Moreover, comparing with nonpandemic H1N1, we identified ten distinct DEGs (AREG, CXCL13, GATM, GPR171, IFI35, IFI47, IFIT3, ORM1, RETNLA, and UBD), which were enriched in immune response and cell surface receptor signalling pathway as well as interacted with immune response-related dysregulated genes during H1N1pdms. Our discoveries will provide comprehensive insights into host responding to pandemic with influenza H1N1 and find broad-spectrum effective treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Disease burden attributable to respiratory syncytial virus outbreaks in long-term care.
- Author
-
Ferrante, Christina, Bancej, Christina, and Atchessi, Nicole
- Subjects
RESPIRATORY syncytial virus ,COVID-19 pandemic ,LONG-term health care ,RESPIRATORY syncytial virus infections ,H1N1 influenza - Abstract
Background: Respiratory syncytial virus (RSV) disease burden is significant among children; however, RSV can also cause excess morbidity and mortality among older adults. Populations in long-term care homes (LTCHs) may be at greater risk of exposure and increased infection severity. The objectives of this article are to identify evidence regarding disease burden and outcome severity attributable to RSV outbreaks among residents and staff in LTCHs; and to highlight reported population and outbreak characteristics. Methods: All types of evidence were eligible for inclusion. Data utilized by included studies was between the end of the 2010 H1N1 influenza pandemic and the beginning of the coronavirus disease 2019 (COVID-19) pandemic. Evidence from the following countries was considered: G7, the European Union, Australia and New Zealand. A total of 167 articles were identified; 58 full texts were analyzed and four sources of evidence were eligible for inclusion. Data related to population characteristics, outbreak type and resident and staff outcomes were manually charted. Results: There is a paucity of evidence sources pertaining to RSV outbreak burden among residents and staff in LTCHs. Outbreak duration ranged from 13 to 21 days. For each outbreak, 4-7 residents had confirmed RSV infection. Attack rates ranged from 12% to 38%. A spectrum of disease attributable to RSV outbreaks in LTCHs was identified, ranging from mild cold-like symptoms to death. Conclusion: Integration of RSV into existing respiratory pathogen surveillance programs is important to characterize susceptibility, transmissibility and virulence of RSV in at-risk populations. There is a need for public health organizations to publish the findings from outbreak investigations to provide evidence to inform RSV outbreak prevention and response in LTCH settings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Venovenous extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: A comparative cohort study in China
- Author
-
Yonghao Xu, Yin Xi, Shuijiang Cai, Yuheng Yu, Sibei Chen, Weijie Guan, Weibo Liang, Hongkai Wu, Weiqun He, Xilong Deng, Yuanda Xu, Rong Zhang, Manshu Li, Jieyi Pan, Zhenting Liang, Ya Wang, Shaofeng Kong, Xiaoqing Liu, Zheng Lv, and Yimin Li
- Subjects
Coronavirus disease 2019 ,H1N1 influenza ,Acute respiratory distress syndrome ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Background: Venovenous extracorporeal membrane oxygenation (VV-ECMO) has been demonstrated to be effective in treating patients with virus-induced acute respiratory distress syndrome (ARDS). However, whether the management of ECMO is different in treating H1N1 influenza and coronavirus disease 2019 (COVID-19)-associated ARDS patients remains unknown. Methods: This is a retrospective cohort study. We included 12 VV-ECMO-supported COVID-19 patients admitted to The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Eighth People's Hospital, and Wuhan Union Hospital West Campus between January 23 and March 31, 2020. We retrospectively included VV-ECMO-supported patients with COVID-19 and H1N1 influenza-associated ARDS. Clinical characteristics, respiratory mechanics including plateau pressure, driving pressure, mechanical power, ventilatory ratio (VR) and lung compliance, and outcomes were compared. Results: Data from 25 patients with COVID-19 (n=12) and H1N1 (n=13) associated ARDS who had received ECMO support were analyzed. COVID-19 patients were older than H1N1 influenza patients (P=0.004). The partial pressure of arterial carbon dioxide (PaCO2) and VR before ECMO initiation were significantly higher in COVID-19 patients than in H1N1 influenza patients (P
- Published
- 2023
- Full Text
- View/download PDF
25. The Effect of Mice Adaptation Process on the Pathogenicity of Influenza A/South Africa/3626/2013 (H1N1)pdm09 Model Strain.
- Author
-
Al Farroukh, Mohammad, Kiseleva, Irina, Stepanova, Ekaterina, Bazhenova, Ekaterina, Krutikova, Elena, Tkachev, Artem, Chistyakova, Anna, Rekstin, Andrey, Puchkova, Ludmila, and Rudenko, Larisa
- Subjects
- *
INFLUENZA , *MICE , *H1N1 influenza , *IMMUNE response , *INFLUENZA A virus , *FLU vaccine efficacy , *SWINE influenza - Abstract
Influenza virus strain A/South Africa/3626/2013 (H1N1)pdm09 (SA-WT) is a non-mouse-adapted model strain that has naturally high pathogenic properties in mice. It has been suggested that the high pathogenicity of this strain for mice could be due to the three strain-specific substitutions in the polymerase complex (Q687R in PB1, N102T in PB2, and E358E/K heterogeneity in PB2). To evaluate the role of these replacements, SA-WT was passaged five times in mouse lungs, and the genome of the mouse-adapted version of the SA-WT strain (SA-M5) was sequenced. SA-M5 lost E358E/K heterogeneity and retained E358, which is the prevalent amino acid at this position among H1N1pdm09 strains. In addition, in the hemagglutinin of SA-M5, two heterogeneous substitutions (G155G/E and S190S/R) were identified. Both viruses, SA-M5 and SA-WT, were compared for their toxicity, ability to replicate, pathogenicity, and immunogenicity in mice. In mice infected with SA-M5 or SA-WT strains, toxicity, virus titer in pulmonary homogenates, and mouse survival did not differ significantly. In contrast, an increase in the immunogenicity of SA-M5 compared to SA-WT was observed. This increase could be due to the substitutions G155G/E and S190S/R in the HA of SA-M5. The prospects for using SA-M5 in studying the immunogenicity mechanisms were also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Experimental infection of pigs and ferrets with "pre-pandemic," human-adapted, and swine-adapted variants of the H1N1pdm09 Influenza A virus reveals significant differences in viral dynamics and pathological manifestations.
- Author
-
Kristensen, Charlotte, Laybourn, Helena A., Crumpton, Jeri-Carol, Martiny, Karen, Webb, Ashley, Ryt-Hansen, Pia, Trebbien, Ramona, Jensen, Henrik E., Nissen, Jakob N., Skovgaard, Kerstin, Webby, Richard J., and Larsen, Lars E.
- Subjects
- *
H1N1 influenza , *INFLUENZA viruses , *FERRET , *INFLUENZA A virus , *SWINE breeding , *INFLUENZA A virus, H1N1 subtype , *HUMAN-to-human transmission - Abstract
Influenza A viruses are RNA viruses that cause epidemics in humans and are enzootic in the pig population globally. In 2009, pig-to-human transmission of a reassortant H1N1 virus (H1N1pdm09) caused the first influenza pandemic of the 21st century. This study investigated the infection dynamics, pathogenesis, and lesions in pigs and ferrets inoculated with natural isolates of swine-adapted, human-adapted, and "pre-pandemic" H1N1pdm09 viruses. Additionally, the direct-contact and aerosol transmission properties of the three H1N1pdm09 isolates were assessed in ferrets. In pigs, inoculated ferrets, and ferrets infected by direct contact with inoculated ferrets, the pre-pandemic H1N1pdm09 virus induced an intermediary viral load, caused the most severe lesions, and had the highest clinical impact. The swine-adapted H1N1pdm09 virus induced the highest viral load, caused intermediary lesions, and had the least clinical impact in pigs. The human-adapted H1N1pdm09 virus induced the highest viral load, caused the mildest lesions, and had the least clinical impact in ferrets infected by direct contact. The discrepancy between viral load and clinical impact presumably reflects the importance of viral host adaptation. Interestingly, the swine-adapted H1N1pdm09 virus was transmitted by aerosols to two-thirds of the ferrets. Further work is needed to assess the risk of human-to-human aerosol transmission of swine-adapted H1N1pdm09 viruses. Author summary: Influenza A viruses (IAVs) have a high evolutionary rate and evolve through genetic drift and reassortment events, elevating their pandemic threat. The last pandemic caused by IAV was a consequence of a spillover of IAV from pigs to humans in 2009 (referred to as H1N1pdm09). The viral and host markers important for host adaptation of IAVs are poorly defined, which makes it difficult to evaluate the pandemic potential of novel swine IAV strains. A method of predicting the risk of human-to-human transmission of IAVs is by using the ferret as an animal model. In this study, we assessed the degree of host adaptation to pigs and ferrets of three different H1N1pdm09 viruses by virological, clinical, and pathological measures. We found that a swine-adapted H1N1pdm09 had the highest viral fitness but the lowest virulence in pigs and that a human-adapted H1N1pdm09 had the highest viral fitness but the lowest virulence in ferrets. In both animal models, we found that an H1N1pdm09 virus resembling a pre-pandemic variant had an intermediary viral fitness but the highest virulence. Our findings indicate that host adaptation is important for the viral fitness and virulence and that an increased viral fitness is not always related with a higher virulence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. The Mobility of Eurasian Avian-like M2 Is Determined by Residue E79 Which Is Essential for Pathogenicity of 2009 Pandemic H1N1 Influenza Virus in Mice.
- Author
-
Wu, Rujuan, Zeng, Xinyu, Wu, Mingqing, Xie, Lixiang, Xu, Guanlong, Mao, Yaqing, Wang, Zhaofei, Cheng, Yuqiang, Wang, Heng'an, Yan, Yaxian, Sun, Jianhe, and Ma, Jingjiao
- Subjects
- *
H1N1 influenza , *INFLUENZA A virus, H1N1 subtype , *EXTRACELLULAR matrix proteins , *POLYACRYLAMIDE gel electrophoresis , *SWINE influenza , *VIRUS diseases - Abstract
In 2009, a novel H1N1 influenza virus caused the first influenza pandemic of the 21st century. Studies have shown that the influenza M gene played important roles in the pathogenicity and transmissibility of the 2009 H1N1 pandemic ((H1N1)pdm09), whilst the underlying mechanism remains unclear. The influenza M gene encodes two proteins, matrix protein 1 and matrix protein 2, which play important roles in viral replication and assembly. In this study, it is found that the M2 protein of the (H1N1)pdm09 virus showed a lower mobility rate than the North America triple-reassortant influenza M2 protein in Polyacrylamide Gel Electrophoresis (PAGE). The site-directed mutations of the amino acids of (H1N1)pdm09 M2 revealed that E79 is responsible for the mobility rate change. Further animal studies showed that the (H1N1)pdm09 containing a single M2-E79K was significantly attenuated compared with the wild-type virus in mice and induced lower proinflammatory cytokines and IFNs in mouse lungs. Further in vitro studies indicated that this mutation also affected NLRP3 inflammasome activation. To reveal the reason why they have different mobility rates, a circular dichroism spectra assay was employed and showed that the two M2 proteins displayed different secondary structures. Overall, our findings suggest that M2 E79 is important for the virus replication and pathogenicity of (H1N1)pdm09 through NLRP3 inflammasome and proinflammatory response. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Antiviral Potential of Azelastine against Major Respiratory Viruses.
- Author
-
Fischhuber, Katrin, Bánki, Zoltán, Kimpel, Janine, Kragl, Natalie, Rössler, Annika, Bolze, Annika, Muellauer, Brigitte, Angerer, Joachim, Nagy, Gábor, Nagy, Eszter, and Szijarto, Valeria
- Subjects
- *
SARS-CoV-2 Omicron variant , *COVID-19 , *VIRUS diseases , *RESPIRATORY syncytial virus , *H1N1 influenza , *INTRANASAL medication , *VIRAL load - Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic and the subsequent increase in respiratory viral infections highlight the need for broad-spectrum antivirals to enable a quick and efficient reaction to current and emerging viral outbreaks. We previously demonstrated that the antihistamine azelastine hydrochloride (azelastine-HCl) exhibited in vitro antiviral activity against SARS-CoV-2. Furthermore, in a phase 2 clinical study, a commercial azelastine-containing nasal spray significantly reduced the viral load in SARS-CoV-2-infected individuals. Here, we evaluate the efficacy of azelastine-HCl against additional human coronaviruses, including the SARS-CoV-2 omicron variant and a seasonal human coronavirus, 229E, through in vitro infection assays, with azelastine showing a comparable potency against both. Furthermore, we determined that azelastine-HCl also inhibits the replication of Respiratory syncytial virus A (RSV A) in both prophylactic and therapeutic settings. In a human 3D nasal tissue model (MucilAirTM-Pool, Epithelix), azelastine-HCl protected tissue integrity and function from the effects of infection with influenza A H1N1 and resulted in a reduced viral load soon after infection. Our results suggest that azelastine-HCl has a broad antiviral effect and can be considered a safe option against the most common respiratory viruses to prevent or treat such infections locally in the form of a nasal spray that is commonly available globally. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. The CombE-IDMS Alternate Potency Method for H5N1 and H5N8 Cell-Based Vaccines.
- Author
-
Donohue, Matthew P., Cao, Zhijun, Bowen, Thomas, Dickinson, Robert, Zhang, Ying, and Qian, Jiang
- Subjects
H1N1 influenza ,VIRAL vaccines ,VACCINES ,SEASONAL influenza ,INFLUENZA vaccines - Abstract
Assaying the potency of inactivated viral influenza vaccines is performed using single radial immunodiffusion, which is the globally accepted release method for potency. Under conditions of a rapidly emerging pandemic, such as the 2009 H1N1 influenza pandemic, a recognized obstacle in the delivery of vaccines to the public is the time needed for the distribution of calibrated SRID reagents (antisera and antigen standards) to vaccine manufacturers. Previously, we first described a novel streamlined MS-based assay, CombE-IDMS, which does not rely on antisera/antibodies or reference antigens, as a potential rapidly deployable alternate potency method through a comparison with SRID on adjuvanted seasonal quadrivalent vaccine cell-based (aQIVc) materials. In this report, we further demonstrate that the CombE-IDMS method can also be applied to measure the potency of pre-pandemic H5N1 and H5N8 monovalent vaccine materials, each subtype both unadjuvanted and adjuvanted, through a forced degradation study. Overall, CombE-IDMS results align with those of the gold standard SRID method on both H5N1 and H5N8 materials under conditions of thermal, pH, oxidative and freeze/thaw stress, lending further evidence for the CombE-IDMS method's suitability as an alternate assay for potency of both seasonal and pandemic influenza vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. A direct contact pig influenza challenge model for assessing protective efficacy of monoclonal antibodies.
- Author
-
McNee, Adam, Vanover, Daryll, Rijal, Pramila, Paudyal, Basudev, Lean, Fabian Z. X., MacLoughlin, Ronan, Núñez, Alejandro, Townsend, Alain, Santangelo, Philip J., and Tchilian, Elma
- Subjects
MONOCLONAL antibodies ,INFLUENZA ,H1N1 influenza ,VIRUS diseases ,SWINE - Abstract
Monoclonal antibodies (mAbs) can be used to complement immunization for the therapy of influenza virus infection. We have established the pig, a natural large animal host for influenza A, with many physiological, immunological, and anatomical similarities to humans, as an appropriate model for testing mAbs. We have evaluated the protective efficacy of the strongly neutralizing human anti-hemagglutinin mAb, 2-12C in the pig influenza model. Intravenous administration of recombinant 2-12C reduced virus load and lung pathology, however, it did not prevent virus nasal shedding and, consequently, transmission. This may be because the pigs were directly infected intranasally with a high dose of the H1N1pdm09 virus. To address this, we developed a contact challenge model in which the animals were given 2-12C and one day later co-housed with donor pigs previously infected intra-nasally with H1N1pdm09. 2-12C pretreatment completely prevented infection. We also administered a lower dose of 2-12C by aerosol to the respiratory tract, but this did not prevent shedding in the direct challenge model, although it abolished lung infection. We propose that the direct contact challenge model of pig influenza may be useful for evaluating candidate mAbs and emerging delivery platforms prior to clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Alterations in Patients' Clinical Outcomes and Respiratory Viral Pathogen Activity following the COVID-19 Pandemic.
- Author
-
Oweidat, Khaled Al, Toubasi, Ahmad A., Alghrabli, Ahmad, Khater, Yasmeen, Saleh, Noor, Albtoosh, Asma S., and Batarseh, Rawan Shafeek
- Subjects
- *
COVID-19 pandemic , *LEUKOCYTE count , *DIASTOLIC blood pressure , *RESPIRATORY infections , *H1N1 influenza - Abstract
Background: Before the COVID-19 pandemic, respiratory pathogens such as influenza, parainfluenza, and respiratory syncytial virus were the most commonly detected viruses among hospitalized patients with respiratory tract infections. Methods: This was a retrospective observational study of inpatients and outpatients who attended Jordan University Hospital and underwent Nasopharyngeal Aspiration (NPA) in the periods from December 2017 to December 2018 and from December 2021 to December 2022. The results of multiplex respiratory pathogen real-time PCR tests for nasopharyngeal swab specimens were extracted from the electronic-based molecular diagnostic laboratory record of JUH. We compared the prevalence of the detected viruses as well as the patients' characteristics and outcomes between the two periods. Results: The total number of included patients was 695. Our analysis showed that a higher percentage of patients with hypertension and diabetes presented before the pandemic compared to the same period after it (p-value < 0.001). The need for O2 devices, white blood cell counts, diastolic blood pressure, and the length of hospital stay were significantly higher among patients who presented before the pandemic (p-value < 0.050). Influenza H1N1 (8.70% vs. 4.03%), influenza B (1.67% vs. 0.25%), parainfluenza (1.00% vs. 0.00%), human metapneumovirus (5.35% vs. 0.76%), adenoviruses (6.35% vs. 3.02%), and coronaviruses (8.70% vs. 3.53%) were detected with higher frequency in the period before the pandemic (p-value = 0.011, 0.045, 0.045, 0.000, 0.035, 0.004). These results were similar in terms of changes in the detection rates of viruses after matching the number of tested patients between the periods before and after the pandemic. Conclusions: We have demonstrated a reduction in the detection of several viruses, which might be due to the increase in public awareness toward infection protection measures after the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Diversity of Upper Respiratory Tract Pathogens in Patients having Flu-Like Symptoms during COVID-19 Pandemic in a Referral Hospital.
- Author
-
RAHMAN, M., AYAZ, K. F. M., ISLAM, S., HASAN, N., RAHIM, R., and HASAN, A.
- Subjects
- *
COVID-19 pandemic , *RESPIRATORY infections , *HUMAN metapneumovirus infection , *PATHOGENIC microorganisms , *H1N1 influenza , *PUBLIC health - Abstract
Background: Upper respiratory tract infections (URTIs) are caused by a wide range of viruses and bacteria, however, produce similar symptoms. Routine molecular tests are not performed and empirical use of antibiotics in treating URTIs is a major public health concern. In attempt to unveil the diversity of upper respiratory tract pathogens in the community during COVID-19 pandemic, we have screened 153 nasopharyngeal swab samples from patients having flu like symptoms. Materials and methods: We tested nasopharyngeal swabs by real-time multiplex PCR for 19 viruses and 3 bacteria using cartridge based rapid PCR platform. Results: Of 153 patients sample tested, 103 (67.32%) had a laboratory-confirmed respiratory pathogen. Of the 153 swabs tested rhinovirus/enterovirus was found 25(16.34%), influenza 18(11.77%), RSV 13(8.5%), SARS-CoV2-15(11.11%), other coronaviruses 11(7.19%), parainfluenza 16(10.45%), human metapneumovirus 8(5.23%). Out of 18 influenza cases influenza A was 17(11.12%) and influenza B was 1(0.65%). Among 17 influenza A viruses H1N1pdm09 strain was 9(5.88%), H3 was 5(3.27%). These data shows that even in COVID-19 pandemic period rhinovirus/enterovirus and Influenza dominated over all other respiratory viruses and as a causative agent bacteria might play very insignificant role in URTIs. Conclusion: Our data provides strong evidence against empiric antibiotic use for treating URTIs and highlights a strong need for improving the diagnostic capacity for URTIs by using more molecular testing in the country. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Ginsenoside Rb1 enhanced immunity and altered the gut microflora in mice immunized by H1N1 influenza vaccine.
- Author
-
Chuanqi Wan, Rufeng Lu, Chen Zhu, Haibo Wu, Guannan Shen, Yang Yang, Xiaowei Wu, Bangjiang Fang, and Yuzhou He
- Subjects
H1N1 influenza ,INFLUENZA vaccines ,GINSENOSIDES ,INFLUENZA A virus, H1N1 subtype ,RESPIRATORY diseases - Abstract
Background. Influenza is an acute infectious respiratory disease caused by the influenza virus that seriously damages human health, and the essential way to prevent influenza is the influenza vaccine. Vaccines without adjuvants produce insufficient specific antibodies and therefore require adjuvants to boost antibody titers. Microbes and hosts are a community that needs to ''promote bacteria,'' which could provide new value for the immune effect. Methods. (1) The H1N1 influenza vaccine, in combination with Ginsenoside Rb1, was co-injected into mice intraperitoneally (I.P.). Then, immunoglobulin G and antibody subtype levels were tested by enzyme-linked immunosorbent assay (ELISA). Moreover, mice were infected with a lethal dose of the H1N1 influenza virus (A/Michi- gan/45/2015), and survival status was recorded for 14 days. Lung tissues were stained by hematoxylin and eosin (H&E), and ELISA detected inflammatory factor expression levels. (2) Mice were immunized with Ginsenoside Rb1 combined with quadrivalent influenza inactivated vaccine(IIV4), and then IgG levels were measured by ELISA. (3) Fresh stool was collected for fecal 16S rDNA analysis. Results. Ginsenoside Rb1 boosted IgG and antibody subtypes in the H1N1 influenza vaccine, improved survival of mice after virus challenge, attenuated lung histopathological damage, and reduced inflammatory cytokines expression in IL-6 and TNF-α. The results of 16S rDNA showed that Rb1 decreased species diversity but increased species richness compared to the PBS group and increased the abundance of Akkermansiaceae and Murbaculaceae at the Family and Genus levels compared with the HA+Alum group. Conclusion. Ginsenoside Rb1 has a boosting effect on the immune efficacy of the H1N1 influenza vaccine and is promising as a novel adjuvant to regulate the microecological balance and achieve an anti-infective effect. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Generation of a DSF-Guided Refolded Bacterially Expressed Hemagglutinin Ectodomain of Influenza Virus A/Puerto Rico/8/1934 H1N1 as a Model for Influenza Vaccine Antigens.
- Author
-
Tofan, Vlad-Constantin, Ermeneanu, Andreea-Laura, Caraș, Iuliana, Lenghel, Alina, Ionescu, Irina-Elena, Țucureanu, Cătălin, Gal, Claudiu, Stăvaru, Crina-Georgeta, and Onu, Adrian
- Subjects
H1N1 influenza ,INFLUENZA vaccines ,INFLUENZA viruses ,INFLUENZA A virus ,HEMAGGLUTININ - Abstract
Influenza virus infections represent an ongoing public health threat as well as an economic burden. Although seasonal influenza vaccines have been available for some decades, efforts are being made to generate new efficient, flexible, and cost-effective technologies to be transferred into production. Our work describes the development of a model influenza hemagglutinin antigen that is capable of inducing protection against viral challenge in mice. High amounts of the H1 hemagglutinin ectodomain, HA
18–528 , were expressed in a bacterial system as insoluble inclusion bodies. Solubilization was followed by a thorough differential scanning fluorimetry (DSF)-guided optimization of refolding, which allows for fast and reliable screening of several refolding conditions, yielding tens of milligrams/L of folded protein. Structural and functional analysis revealed native-like folding as well as the presence of a mix of monomers and oligomers in solution. Mice immunized with HA18–528 were protected when exposed to influenza A virus as opposed to mice that received full-length denatured protein. Sera of mice immunized with HA18–528 showed both high titers of antigen-specific IgG1 and IgG2a isotypes as well as viral neutralization activity. These results prove the feasibility of the recombinant bacterial expression system coupled with DSF-guided refolding in providing influenza hemagglutinin for vaccine development. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
35. Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml
- Author
-
Maria Elena Romero Ibarguengoitia, Principal Investigator/Research Director
- Published
- 2022
36. Editorial: Zoonotic negative-sense RNA viruses.
- Author
-
Edwards, Sarah J. and Luczo, Jasmina M.
- Subjects
RNA viruses ,RIFT Valley fever ,VIRAL tropism ,H7N9 Influenza ,VETERINARY medicine ,AVIAN influenza A virus ,H1N1 influenza ,VIRAL shedding - Abstract
This editorial published in Frontiers in Veterinary Science discusses the threat of zoonotic negative-sense RNA viruses to animal and human health. It emphasizes the need to understand factors contributing to their emergence, infection, and spill-over. The article presents research findings on vaccination strategies, immune imprinting, oral mucosal immunity, avian influenza viruses, swine influenza viruses, and Rift Valley fever phlebovirus. The authors stress the importance of understanding viral evolution and the host response to infection for pandemic preparedness and the development of diagnostic tools and countermeasures. The document also provides a list of references for further research on avian influenza H5N1 and the risks associated with the human-animal interface. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
37. Human behavior and disease dynamics.
- Author
-
Bergstrom, Carl T. and Hanage, William P.
- Subjects
- *
HUMAN behavior , *H1N1 influenza , *VACCINE manufacturing , *COMMUNICABLE diseases - Published
- 2024
- Full Text
- View/download PDF
38. Vaccine-induced neutralizing antibody responses to seasonal influenza virus H1N1 strains are not enhanced during subsequent pandemic H1N1 infection.
- Author
-
Mooij, Petra, Mortier, Daniella, Aartse, Aafke, Murad, Alexandre B., Correia, Ricardo, Roldão, António, Alves, Paula M., Fagrouch, Zahra, Eggink, Dirk, Stockhofe, Norbert, Engelhardt, Othmar G., Verschoor, Ernst J., van Gils, Marit J., Bogers, Willy M., Carrondo, Manuel J. T., Remarque, Edmond J., and Koopman, Gerrit
- Subjects
INFLUENZA A virus, H1N1 subtype ,SEASONAL influenza ,ANTIBODY formation ,VIRAL shedding ,HUMORAL immunity ,H1N1 influenza ,PANDEMICS ,PARAINFLUENZA viruses ,RABIES virus - Abstract
The first exposure to influenza is presumed to shape the B-cell antibody repertoire, leading to preferential enhancement of the initially formed responses during subsequent exposure to viral variants. Here, we investigated whether this principle remains applicable when there are large genetic and antigenic differences between primary and secondary influenza virus antigens. Because humans usually have a complex history of influenza virus exposure, we conducted this investigation in influenza-naive cynomolgus macaques. Two groups of six macaques were immunized four times with influenza virus-like particles (VLPs) displaying either one (monovalent) or five (pentavalent) different hemagglutinin (HA) antigens derived from seasonal H1N1 (H1N1) strains. Four weeks after the final immunization, animals were challenged with pandemic H1N1 (H1N1pdm09). Although immunization resulted in robust virus-neutralizing responses to all VLP-based vaccine strains, there were no cross-neutralization responses to H1N1pdm09, and all animals became infected. No reductions in viral load in the nose or throat were detected in either vaccine group. After infection, strong virus-neutralizing responses to H1N1pdm09 were induced. However, there were no increases in virus-neutralizing titers against four of the five H1N1 vaccine strains; and only a mild increase was observed in virus-neutralizing titer against the influenza A/Texas/36/91 vaccine strain. After H1N1pdm09 infection, both vaccine groups showed higher virus-neutralizing titers against two H1N1 strains of intermediate antigenic distance between the H1N1 vaccine strains and H1N1pdm09, compared with the naive control group. Furthermore, both vaccine groups had higher HA-stem antibodies early after infection than the control group. In conclusion, immunization with VLPs displaying HA from antigenically distinct H1N1 variants increased the breadth of the immune response during subsequent H1N1pdm09 challenge, although this phenomenon was limited to intermediate antigenic variants. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Carambolaside W Inhibited H1N1 Influenza Virus-Induced Oxidative Stress through STAT-3/BCL-XL Signaling Pathway.
- Author
-
Su, Jingyao, Lai, Jia, Li, Jiali, Liu, Xia, Chen, Haitian, Li, Chuqing, Zhu, Bing, Jia, Xuchao, and Li, Yinghua
- Subjects
- *
INFLUENZA A virus, H1N1 subtype , *OXIDATIVE stress , *VIRUS diseases , *CHEMICAL formulas , *CELLULAR signal transduction - Abstract
The H1N1 influenza virus is highly infectious and pathogenic, and in recent years, it has often presented seasonal mass outbreaks of infection. People infected with H1N1 will develop a high fever and other respiratory infection symptoms. If not treated in time, complications such as pneumonia may occur. In this study, we focused on developing drugs that can effectively fight against with H1N1 virus. A flavonoid glycoside was extracted from the carambola, then characterized by HR-ESI-MS with the molecular formula C47H58O2, and named carambolaside W. The flavonoid glycosides were found to have good anti-H1N1 influenza virus effects. In this study, we verified that carambolaside W has low toxicity and can effectively inhibit influenza virus replication in vitro. H1N1 virus infection induces intracellular oxidative stress damage to accelerate disease progression. The results showed that carambolaside W effectively inhibited the oxidative stress caused by H1N1 infection. The Western blot assay also revealed that carambolaside W alters the expression of apoptosis-related proteins in vitro and exerts a good anti-H1N1 influenza virus effect. In summary, carambolaside W is a low-toxicity natural flavonoid that can effectively treat the H1N1 influenza virus as a potential anti-H1N1 virus agent. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Human-to-swine introductions and onward transmission of 2009 H1N1 pandemic influenza viruses in Brazil.
- Author
-
Junqueira, Dennis Maletich, Tochetto, Caroline, Anderson, Tavis K., Gava, Danielle, Haach, Vanessa, Cantão, Maurício E., Vincent Baker, Amy L., and Schaefer, Rejane
- Subjects
H1N1 influenza ,INFLUENZA A virus, H1N1 subtype - Abstract
Introduction: Once established in the human population, the 2009 H1N1 pandemic virus (H1N1pdm09) was repeatedly introduced into swine populations globally with subsequent onward transmission among pigs. Methods: To identify and characterize human-to-swine H1N1pdm09 introductions in Brazil, we conducted a large-scale phylogenetic analysis of 4,141 H1pdm09 hemagglutinin (HA) and 3,227 N1pdm09 neuraminidase (NA) gene sequences isolated globally from humans and swine between 2009 and 2022. Results: Phylodynamic analysis revealed that during the period between 2009 and 2011, there was a rapid transmission of the H1N1pdm09 virus from humans to swine in Brazil. Multiple introductions of the virus were observed, but most of them resulted in self-limited infections in swine, with limited onward transmission. Only a few sustained transmission clusters were identified during this period. After 2012, there was a reduction in the number of human-to-swine H1N1pdm09 transmissions in Brazil. Discussion: The virus underwent continuous antigenic drift, and a balance was established between swine-to-swine transmission and extinction, with minimal sustained onward transmission from humans to swine. These results emphasize the dynamic interplay between human-to-swine transmission, antigenic drift, and the establishment of swine-to-swine transmission in shaping the evolution and persistence of H1N1pdm09 in swine populations [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Evaluation of an identification method for the SARS-CoV-2 Delta variant based on the amplification-refractory mutation system.
- Author
-
Qin Zhang, Runjie Qiao, Jiaojiao Niu, Xia Xiong, Nan Wang, Ruixian Zhang, Sha Luo, Yuwan Guo, Zhonghua Liu, Li Peng, Shaoduo Zhang, Guolei Tan, Keyu Song, Mei Sun, Lulu Xu, Rong Zhang, and Xuping Wu
- Subjects
SARS-CoV-2 Delta variant ,SARS-CoV-2 ,H1N1 influenza ,EVALUATION methodology ,SARS-CoV-2 Omicron variant - Abstract
The Delta variant of SARS-CoV-2 dominated the COVID-19 pandemic due to its high viral replication capacity and immune evasion, causing massive outbreaks of cases, hospitalizations, and deaths. Currently, variant identification is performed mainly by sequencing. However, the high requirements for equipment and operators as well as its high cost have limited its application in underdeveloped regions. To achieve an economical and rapid method of variant identification suitable for undeveloped areas, we applied an amplification-refractory mutation system (ARMS) based on PCR for the detection of novel coronavirus variants. The results showed that this method could be finished in 90 min and detect as few as 500 copies/mL and not react with SARS-Coronavirus, influenza A H1N1(2009), and other cross-pathogens or be influenced by fresh human blood, α-interferon, and other interfering substances. In a set of double-blind trials, tests of 262 samples obtained from patients confirmed with Delta variant infection revealed that our method was able to accurately identify the Delta variant with high sensitivity and specificity. In conclusion, the ARMS-PCR method applied in Delta variant identification is rapid, sensitive, specific, economical, and suitable for undeveloped areas. In our future study, ARMS-PCR will be further applied in the identification of other variants, such as Omicron. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Genetic characterization and whole-genome sequencing-based genetic analysis of influenza virus in Jining City during 2021-2022.
- Author
-
Libo Li, Tiantian Liu, Qingchuan Wang, Yi Ding, Yajuan Jiang, Zengding Wu, Xiaoyu Wang, Huixin Dou, Yongjian Jia, and Boyan Jiao
- Subjects
INFLUENZA viruses ,H1N1 influenza ,NUCLEOTIDE sequencing ,ANTIGENIC variation ,POLYMERASE chain reaction ,NUCLEIC acids - Abstract
Background: The influenza virus poses a significant threat to global public health due to its high mutation rate. Continuous surveillance, development of new vaccines, and public health measures are crucial in managing and mitigating the impact of influenza outbreaks. Methods: Nasal swabs were collected from individuals with influenza-like symptoms in Jining City during 2021-2022. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect influenza A viruses, followed by isolation using MDCK cells. Additionally, nucleic acid detection was performed to identify influenza A H1N1, seasonal H3N2, B/Victoria, and B/Yamagata strains. Whole-genome sequencing was conducted on 24 influenza virus strains, and subsequent analyses included characterization, phylogenetic construction, mutation analysis, and assessment of nucleotide diversity. Results: A total of 1,543 throat swab samples were collected. The study revealed the dominance of the B/Victoria influenza virus in Jining during 2021-2022. Whole-genome sequencing showed co-prevalence of B/Victoria influenza viruses in the branches of Victoria clade 1A.3a.1 and Victoria clade 1A.3a.2, with a higher incidence observed in winter and spring. Comparative analysis demonstrated lower similarity in the HA, MP, and PB2 gene segments of the 24 sequenced influenza virus strains compared to the Northern Hemisphere vaccine strain B/Washington/02/2019. Mutations were identified in all antigenic epitopes of the HA protein at R133G, N150K, and N197D, and the 17-sequence antigenic epitopes exhibited more than 4 amino acid variation sites, resulting in antigenic drift. Moreover, one sequence had a D197N mutation in the NA protein, while seven sequences had a K338R mutation in the PA protein. Conclusion: This study highlights the predominant presence of B/Victoria influenza strain in Jining from 2021 to 2022. The analysis also identified amino acid site variations in the antigenic epitopes, contributing to antigenic drift. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Vitamin D promotes epithelial tissue repair and host defense responses against influenza H1N1 virus and Staphylococcus aureus infections.
- Author
-
Liao, Shumin, Huang, Yanhong, Zhang, Jinxiu, Xiong, Qinglan, Chi, Mengshi, Yang, Liang, Zhang, Junhang, Li, Liang, and Fan, Yunping
- Subjects
- *
STAPHYLOCOCCUS aureus infections , *EPITHELIUM , *CELL junctions , *H1N1 influenza , *VIRUS diseases , *CANCER cell differentiation - Abstract
Background: Early studies indicated that vitamin D (VD) exerted pleiotropic extra-skeletal effects in the airway, but the definite linkage between VD deficiency and airway host responses remains unclear. Methods: 142 cases of clinical data from Department of Otolaryngology, the Seventh Affiliated Hospital of Sun Yat-sen University, were collected to characterize the relationship between VD deficiency and chronic rhinosinusitis (CRS). Based on the clinical observations, 2.5-D airway epithelial organoids cultured at the air–liquid interface (ALI) were used to simulate the effects of VD treatment in the development of airway epithelium and the modulation of the host responses against influenza H1N1 virus (representing viral infections) and Staphylococcus aureus (representing bacterial infections) infections in the airway. The intrinsic mechanisms of VD deficiency underlying epithelial remodeling were mapped by transcriptomic as well as proteomic analyses. Results: In this study we observed prevailing VD deficiency among inpatients suffering from CRS, a common disease predominantly characterized by epithelial impairment and remodeling. Relative to control organoids cultured without VD, long-term incubation with VD accelerated basal cell proliferation during nasal epithelial development. Under infectious conditions, VD treatment protected the organoids against influenza H1N1 virus and Staphylococcus aureus invasions by reinforcing the respiratory host defenses, including upregulation of LL37, suppression (or inhibition) of proinflammatory cytokines, strengthening of epithelial integrity, and mucociliary clearance. In silico analysis of transcriptomics and proteomics suggested that VD modulated the epithelial development and remodeling, involving epithelial cell proliferation/differentiation, epithelial–mesenchymal transition (EMT), and cytokine signaling in the immune system, as well as responses to microbe, cell junction organization, and extracellular matrix organization via PTEN signaling, independent of TGF-β signaling. Conclusions: Our findings emphasize the importance of managing VD deficiency in clinical settings for the sake of alleviating pathological epithelial remodeling. Vitamin D promotes epithelial tissue repair and host defense responses against influenza H1N1 and Staphylococcus aureus infections. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Epidemiology and Outcomes of HIN1 Pneumonia in ICU.
- Author
-
Golagana, Vinya, Venkataraman, Ramesh, Mani, Ashwin K., Rajan, Ebenezer Rabindra, Ramakrishnan, Nagarajan, and Vidyasagar, Dedeepiya Devaprasad
- Subjects
- *
H1N1 influenza , *INTENSIVE care units , *REVERSE transcriptase polymerase chain reaction , *SCIENTIFIC observation , *AUDIOLOGY , *RETROSPECTIVE studies , *APACHE (Disease classification system) , *SYMPTOMS , *DESCRIPTIVE statistics , *LONGITUDINAL method - Abstract
Introduction: Pandemic influenza H1N1/09 emerged for the first time in April 2009 and has spread widely across India since then. The number of cases have increased over time with the increasing need for respiratory support, causing significant morbidity and mortality. We evaluated the clinical course and outcomes of patients infected with Influenza A (H1N1) admitted to three multidisciplinary intensive care units (ICU) in Chennai. Materials and methods: We performed a combined retrospective and prospective observational study of all patients admitted with H1N1 pneumonia at three multidisciplinary ICUs in Chennai from October 1, 2018, to January 31, 2019. Data including demographics, risk factors, and clinical courses were recorded. Outcome data including mortality was tracked up to 28 days. Results: A total of 167 patients were admitted during the study period of which 154 were included in this analysis. The mean age of presentation was 58.2 ± 15.6 years and 59.1% of them were males. The mean acute physiology and chronic health evaluation (APACHE) IV and sequential organ failure assessment (SOFA) scores were 62.8 ± 23.2 and 5.8 ± 3.9 respectively. Oxygen delivery devices were required in 25.3% for a mean duration of 26.5 ± 5.7 hours. Non-invasive ventilation or high-flow nasal cannula (HFNC) was needed in 33.1% of patients for 59.9 ± 64.5 hours. The proportion of patients requiring mechanical ventilation was 41.6%. Rescue measures in the form of proning, use of inhaled nitric oxide (iNO), and extracorporeal membrane oxygenation (ECMO) were initiated for refractory hypoxemia in 26.6%, 14.1%, and 6.3% respectively. The mean duration of ventilator support was 8.5 ± 8 days. Tracheostomy was required in 20.3% of patients and 7.8% were ventilator dependent at 28 days. The mean ICU and Hospital length of stay were 8.3 ± 10.3 and 12.2 ± 14.1 days respectively and overall 28-day mortality was 20.1%. Conclusion: A significant proportion of H1N1 patients admitted to the ICU required high-level respiratory support including non-invasive ventilation (NIV), HFNC, or invasive ventilation. Deployment of rescue therapies was common and the overall mortality rate was similar to those reported from Western countries. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Variability in Donor Lung Culture and Relative Humidity Impact the Stability of 2009 Pandemic H1N1 Influenza Virus on Nonporous Surfaces.
- Author
-
Zhihong Qian, Morris, Dylan H., Avery, Annika, Kormuth, Karen A., Le Sage, Valerie, Myerburg, Michael M., Lloyd-Smith, James O., Marr, Linsey C., and Lakdawala, Seema S.
- Subjects
- *
INFLUENZA A virus, H1N1 subtype , *H1N1 influenza , *HUMIDITY , *LUNGS , *INFLUENZA viruses , *COPPER - Abstract
Respiratory viruses can be transmitted by multiple modes, including contaminated surfaces, commonly referred to as fomites. Efficient fomite transmission requires that a virus remain infectious on a given surface material over a wide range of environmental conditions, including different relative humidities. Prior work examining the stability of influenza viruses on surfaces has relied upon virus grown in media or eggs, which does not mimic the composition of virus-containing droplets expelled from the human respiratory tract. In this study, we examined the stability of the 2009 pandemic H1N1 (H1N1pdm09) virus on a variety of nonporous surface materials at four different humidities. Importantly, we used virus grown in primary human bronchial epithelial cell (HBE) cultures from different donors to recapitulate the physiological microenvironment of expelled viruses. We observed rapid inactivation of H1N1pdm09 on copper under all experimental conditions. In contrast to copper, viruses were stable on polystyrene plastic, stainless steel, aluminum, and glass, at multiple relative humidities, but greater decay on acrylonitrile butadiene styrene (ABS) plastic was observed at short time points. However, the half-lives of viruses at 23% relative humidity were similar among noncopper surfaces and ranged from 4.5 to 5.9 h. Assessment of H1N1pdm09 longevity on nonporous surfaces revealed that virus persistence was governed more by differences among HBE culture donors than by surface material. Our findings highlight the potential role of an individual's respiratory fluid on viral persistence and could help explain heterogeneity in transmission dynamics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Sowing the seeds of a pandemic?: Mammalian pathogenicity and transmissibility of H1 variant influenza viruses from the swine reservoir
- Author
-
Pulit-Penaloza, Joanna A, Belser, Jessica A, Tumpey, Terrence M, and Maines, Taronna R
- Published
- 2019
47. ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS (InfluCOV_ECMO)
- Author
-
Vito Fanelli MD, PhD, MD, PhD
- Published
- 2021
48. All‐cause mortality and Japan's early countermeasures: Authors' reply.
- Author
-
Kaneda, Yudai and Takahashi, Kenzo
- Subjects
MORTALITY ,PANDEMIC preparedness ,COVID-19 pandemic ,H1N1 influenza ,MEDICAL personnel ,ASPIRATION pneumonia - Published
- 2024
- Full Text
- View/download PDF
49. Comparison of COVID-19 and H1N1 Influenza Pneumonia
- Author
-
Yueqing People's Hospital of Zhejiang Province, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Ruian People's Hospital of Zhejiang Province, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Kecheng People's Hospital of Quzhou city, Zhejiang Province, Pingyang People's Hospital of Zhejiang Province, and The First People's Hospital of Yuhang District, Hangzhou, Zhejiang Province
- Published
- 2021
50. The Aqueous Leaf Extract of the Medicinal Herb Costus speciosus Suppresses Influenza A H1N1 Viral Activity under In Vitro and In Vivo Conditions.
- Author
-
Senevirathne, Amal, Jayathilaka, E. H. T. Thulshan, Haluwana, D. K., Chathuranga, Kiramage, Senevirathne, Mahinda, Jeong, Ji-Soo, Kim, Tae-Won, Lee, Jong-Soo, and De Zoysa, Mahanama
- Subjects
- *
H1N1 influenza , *HERBAL medicine , *SEASONAL influenza , *HIGH performance liquid chromatography , *CHLOROGENIC acid , *PLANT viruses - Abstract
This study investigated the antiviral activity of aqueous leaf extract of Costus speciosus (TB100) against influenza A. Pretreatment of TB100 in RAW264.7 cells enhanced antiviral activity in an assay using the green fluorescence-expressing influenza A/Puerto Rico/8/1934 (H1N1) virus. The fifty percent effective concentration (EC50) and fifty percent cytotoxic concentration (CC50) were determined to be 15.19 ± 0.61 and 117.12 ± 18.31 µg/mL, respectively, for RAW264.7 cells. Based on fluorescent microscopy, green fluorescence protein (GFP) expression and viral copy number reduction confirmed that TB100 inhibited viral replication in murine RAW264.7 and human A549 and HEp2 cells. In vitro pretreatment with TB100 induced the phosphorylation of transcriptional activators TBK1, IRF3, STAT1, IKB-α, and p65 associated with interferon pathways, indicating the activation of antiviral defenses. The safety and protective efficacy of TB100 were assessed in BALB/c mice as an oral treatment and the results confirmed that it was safe and effective against influenza A/Puerto Rico/8/1934 (H1N1), A/Philippines/2/2008 (H3N2), and A/Chicken/Korea/116/2004 (H9N2). High-performance liquid chromatography of aqueous extracts led to the identification of cinnamic, caffeic, and chlorogenic acids as potential chemicals for antiviral responses. Further confirmatory studies using these acids revealed that each of them confers significant antiviral effects against influenza when used as pretreatment and enhances the antiviral response in a time-dependent manner. These findings suggest that TB100 has the potential to be developed into an antiviral agent that is effective against seasonal influenza. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.